INmune Bio
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -52 | -56 | -28 | |
EBITDA | -1,173 | -5,355 | -5,208 | -6,472 |
EBIT | -1,273 | -5,407 | -5,264 | -6,472 |
Net Income | -1,273 | -5,407 | -5,264 | -6,472 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -3,605 | -3,403 | -3,660 | -5,632 |
Cash | 18,411 | 21,358 | 24,751 | 27,734 |
Basic Shares | 26,718 | 26,585 | 26,585 | 26,585 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $50 | $14 | $155 | $374 |
Gross Profit | 50 | 14 | 155 | 374 |
EBITDA | -45,849 | -41,529 | -267 | -27,299 |
EBIT | -45,933 | -42,082 | -30,008 | -25,951 |
Net Income | -45,933 | -42,082 | -30,008 | -28,647 |
Net Change In Cash | 50 | 14 | 155 | 374 |
Cost of Revenue | -21,957 | |||
Free Cash Flow | -23,624 | -33,361 | -11,980 | -22,686 |
Cash | 24,751 | 20,922 | 35,848 | 52,153 |
Basic Shares | 26,585 | 19,944 | 17,981 | 17,927 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.05 |
2026-03-31 | -$0.20 |
2025-12-31 | -$0.18 |
2025-09-30 | -$0.24 |